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Abstract 27 
 28 
Variable exposure to anti-tuberculosis (TB) drugs, partially driven by genetic factors, may be 29 
associated with poor clinical outcomes. Previous studies have suggested an influence of the SLCO1B1 30 
locus on the plasma area under the concentration-time curve (AUC) of rifampicin.  We evaluated the 31 
contribution of Single Nucleotide Polymorphisms (SNPs) in SLCO1B1 and other candidate genes 32 
(AADAC, CES-1) to inter-individual pharmacokinetic variability in Malawi. 174 adults with pulmonary 33 
TB underwent sampling of plasma rifampicin concentrations at 2- and 6-hours post-dose. Data from 34 
a prior cohort of 47 intensively sampled, similar patients from the same setting were available to 35 
support population pharmacokinetic model development in NONMEM v7.2©, using a two-stage 36 
strategy to improve information during the absorption phase. Contrary to recent studies in South 37 
Africa and Uganda, SNPs in SLCO1B1 did not explain variability in AUC0-∞ of rifampicin. No 38 
pharmacokinetic associations were identified with AADAC or CES-1 SNPs, which were rare in the 39 
Malawian population.  Pharmacogenetic determinants of rifampicin exposure may vary between 40 
African populations. SLCO1B1 and other novel candidate genes, as well as non-genetic sources of 41 
inter-individual variability, should be further explored in geographically diverse, adequately powered 42 
cohorts. 43 
 44 
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Introduction 46 
 47 
Although effective chemotherapy for tuberculosis (TB) has been available for several decades, cure 48 
rates are variable, remaining at 34-76% in many countries (1-6). The traditional view that treatment 49 
failure, relapse and emergence of antimicrobial resistance are predominantly driven by poor 50 
adherence has been challenged by reports that inter-individual variability in pharmacokinetic (PK) 51 
exposure to rifampicin (RIF) accounts for some unfavourable outcomes, even amongst patients who 52 
do not miss doses of medication (7).   53 
  54 
Existing clinical data show up to 10-fold inter-individual variability in the plasma PK indices of key 55 
drugs, especially RIF (8-11). Maximum plasma concentration (Cmax) and area under the 56 
concentration-time curve (AUC) measurements are often reported as “low” suggesting that some 57 
patients are under-dosed according to currently clinical recommendations. Patient physiology, co-58 
morbidities, concomitant medications and dietary intake all influence drug exposure. However, 59 
genetic polymorphisms in drug metabolising enzymes and transporters may explain up to 30% of PK 60 
variability for all drugs (12-14).  Although Africans have the highest degree of genetic diversity 61 
worldwide (15) and sub-Saharan Africa accounts for a large proportion of global TB incidence and 62 
mortality, data on the pharmacogenetic determinants of anti-tuberculosis drug exposure amongst 63 
TB-endemic African populations are sparse. 64 
 65 
RIF is believed to be the decisive drug that enables short-course chemotherapy. Metabolism by 66 
hepatic esterases and biliary excretion of RIF occurs after first-pass metabolism and hepatocellular 67 
uptake, which may be primarily mediated by organic anion-transporting polypeptide 1B1 (OATP1B1), 68 
the product of the gene SLCO1B1 (16-17). Reports from South Africa and Uganda suggested that two 69 
SLCO1B1 Single Nucleotide Polymorphisms (SNPs), rs11045819, rs4149032, are common in African 70 
patients and associated with reduced RIF plasma exposure (18-20). However, a recent study from a 71 
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TB-endemic population in southern India reported lower variant allele frequency of these SNPs than 72 
the prior African work and no genotypic effect on the pharmacokinetics of RIF (21).  More data from 73 
a broader range of global settings are required to assess the effect of SLCO1B1 genetics on 74 
rifampicin exposure.       75 
 76 
Within the hepatocyte, RIF is thought to be metabolised by microsomal hepatic esterases, which 77 
have been incompletely characterised to date. In vitro data have suggested that the serine esterase 78 
arylacetamide deacetylase (AADAC) may mediate 25-deacetylation of rifamycins (22) and that SNPs 79 
in the genes encoding hepatic microsomal AADAC may alter RIF clearance (23). Alternative routes to 80 
breaking ester linkages in RIF metabolism may involve the carboxyesterase (e.g. CES-1 and -2) 81 
enzymes which are relatively abundant in the liver and gut. There are no clinical data to define the 82 
effect of SNPs in AADAC or CES genes on plasma RIF exposure.  83 
 84 
To assess previously described pharmacogenetic effects in a new population, and evaluate the 85 
contribution of unexplored polymorphisms in other key metabolic processes, we assessed the 86 
impact of critical SNPs in the candidate genes SLCO1B1, AADAC and CES-1 on plasma exposure to RIF 87 
amongst Malawian adults with smear-positive pulmonary TB. To maximise our study size with 88 
limited resources in a low income setting, participants underwent sparse PK sampling at two time 89 
points. Prior intensive PK data from the same population facilitated use of two-stage population 90 
pharmacokinetic methods to improve information on RIF exposure, particularly during the 91 
absorption phase.   92 
 93 
Results 94 
 95 
The sparsely sampled dataset comprised 174 participants. 121 (69.5%) were male, median age was 96 
30 (range: 17-61) years and median weight was 52.0 (range: 34-74) kg. 98 (56.3%) were HIV-infected 97 
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with a median CD4 count of 174 (range: 6-783) cells/µl. 28/98 (28.6%) HIV-infected patients were on 98 
Antiretroviral Therapy (ART) at the time of recruitment. Full details are provided in Table 1. 99 
 100 
The intensely sampled dataset used for the first stage of pharmacokinetic model-fitting comprised 101 
47 participants. 24 (52%) were male, median age was 34 (range: 16-60) years and median weight 102 
was 52.5 (range: 35.8-74.3) kg. 30 (65%) were HIV-infected and 13/47 (27.7%) were on ART at the 103 
time of recruitment. All participants from both cohorts were black Africans newly diagnosed with 104 
tuberculosis at Queen Elizabeth Central Hospital (QECH), Blantyre, Malawi.  105 
 106 
In the first stage of the pharmacokinetic analysis, performed with the intensively sampled dataset 107 
alone, a one-compartment model appeared most appropriate with a transit compartment model 108 
best describing the absorption phase (Δ Objective Function Value (OFV) = 111). Inter-individual 109 
random effects (IIV) were supported for apparent clearance (CL/F) apparent volume of distribution 110 
(V/F) and absorption mean transit time (MMT).  111 
 112 
The second stage of the analysis utilised only the sparsely-sampled dataset. Due to the relative lack 113 
of information on the absorption phase from this dataset, model parameters relating to absorption 114 
were fixed at the values estimated in the first stage of the analysis. Model refinement involved a 115 
comprehensive search of the covariates available. The inclusion of an allometric scaling weight 116 
model decreased the OFV significantly (ΔOFV =7). The only demographic covariate which 117 
significantly affected the model fit was sex, with a drop of OF of 10.5 (P<0.01). The final model 118 
showed an increase of clearance of 17% in male patients, resulting in a decreased of average AUC of 119 
3% in males.  Full PK parameters of the final two stage RIF model are included in Tables 2 and 3. 120 
 121 
 A Visual Predictive Check (VPC) of 1000 simulated datasets indicated that the final model performed 122 
adequately (Figure 1). The values of RIF AUC0-∞  and CMax were obtained using empirical Bayesian 123 
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estimates of the individual parameters. A predicted RIF AUC0-∞ was generated for each subject using 124 
their estimated CL/F from the final model (Dose/[CL/F] = AUC). The median predicted AUC0-∞ was 125 
29.9 µg.hr/ml, with a range of 19.7 µg.hr/ml to 63.4 µg.hr/ml. The median CMax was 4.8 µg/ml with 126 
a range of 1.4 µg/ml to 10.9 µg/ml. 127 
 128 
Candidate SNPS in the SLCO1B1, AADAC and CES-1 loci were assessed. The distribution of alleles at 129 
these loci is presented in Table 1.  The rs11045819 SLCO1B1 SNP was rare, existing at an overall 130 
frequency of 0.07 whilst the rs4149032 SLCO1B1 SNP had a minor allele frequency of 0.32. No 131 
subjects possessed the variant rs61733692 AADAC SNP whilst the rs1803155 AADAC SNP had a 132 
minor allele frequency of 0.25. Only one patient was heterozygote for the variant rs121493368 CES-1 133 
SNP.  Since the metabolic action of these genes is believed to be exerted largely during first-pass 134 
metabolism, their impact on relative bioavailability (F) was tested as well as CL/F.  Additive, 135 
dominant and recessive models of effect were tested for each SNP.  Inclusion of SLCO1B1 genotypes 136 
did not significantly improve the model fit. The AADAC SNPs and haplotype, or the CES-1 SNP did not 137 
significantly alter the RIF model fit; as would be anticipated from the very low variant allele 138 
frequency in our study population.  139 
 140 
Discussion   141 
 142 
This study is the first pharmacogenetic analysis of anti-tuberculosis therapy from Malawi, the largest 143 
such study to date using a population modelling approach to relate pharmacogenetic 144 
polymorphisms to plasma AUC and the first to evaluate the effect of SNPs in AADAC in this context. 145 
The results of our analysis draw attention the importance of: fully considering SNP diversity within 146 
Africa; the complexity of competing metabolic processes; and recognising the limitations of 147 
observational pharmacogenetic designs.  148 
 149 
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A two-stage population PK modelling approach was used to quantify RIF exposure amongst adult 150 
patients on treatment for pulmonary TB, benefiting from the availability of data from a pre-existing, 151 
exchangeable population of intensively sampled patients (24). A sequential rather than simultaneous 152 
approach was used to handle all the data because pharmacogenetic information was unavailable for 153 
the intensive dataset, reducing the value of combined modelling with incomplete covariates. 154 
The two-step approach enabled plausible and efficient estimation of plasma AUC from sparsely 155 
sampled participants, which is a more reliable measure of total drug exposure than a single “peak” 156 
concentration at a fixed time after dosing. Plasma AUC demonstrated up to 6-fold variability 157 
between patients, like previous African cohorts. RIF is a crucial component of the current first-line 158 
anti-tuberculosis regimen. In general, AUC/MIC (minimum inhibitory concentration) is the PK index 159 
most closely related to the bactericidal activity of RIF (25), and a recent South African study reported 160 
a threshold of AUC of RIF (≤ 13 µg.hr/ml) to be an independent predictor of poor outcome (26) 161 
Therefore, identifying host pharmacogenetic factors which influence the AUC of this key drug may 162 
help identify individuals at risk of treatment failure, and explain differences in treatment outcomes 163 
between populations. 164 
 165 
The SLCO1B1 locus encodes an organic anion transporter (OATP1B1) implicated in the hepatic 166 
uptake of several drugs and contains at least 17 non-synonymous SNPs. Much interest in Europe has 167 
focused on the role of rs4149056 (521T>C, *5) in toxicity of statin therapy (27), whilst studies in 168 
South Africa and Uganda have implicated two SLCO1B1 SNPs (rs4149032 and rs11045819) in 169 
reduced RIF exposure (18-20). However, in keeping with a recent report from southern India (21), 170 
inclusion of these genotypes did not significantly improve the PK model fit for RIF in our study. 171 
 172 
There are potential explanations for the discrepant results between SLCO1B1 studies. The rs4149032 173 
variant allele frequency was higher in South Africa (0.70-0.76), where an association with RIF was 174 
reported, than our Malawian study (0.32) or southern India (0.46) where the results were negative. 175 
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Similarly, the rs11045819 variant allele frequency was higher in Uganda (0.15) that Malawi (0.07) or 176 
India (0.01). Therefore, it is possible that populations with lower allele frequencies require a larger 177 
sample size for adequate power to detect a pharmacokinetic effect. Additionally, whilst rs11045819 178 
is believed to be functional (463C>A, *4), rs4149032 is an intronic SNP of unclear functional status 179 
which, in European populations, is in strong linkage disequilibrium with rs11045819 (28). However, 180 
these SNPs had a low level of linkage disequilibrium (D’ 0.16) in Malawi, echoing findings from South 181 
Africa (18) and southern India (21). There are large differences in linkage disequilibrium worldwide 182 
and within Africa (15), so it is possible that previously recognised SNPs may tag functional genes in 183 
some populations but not others.  184 
 185 
AADAC, a microsomal serine deacetylase expressed mainly in the liver and gastrointestinal tract, is 186 
responsible for 25-deacetylation of rifamycins in vitro (23). Previous pre-clinical studies identified 187 
that expression of the AADAC*3 allele (rs1803155/rs61733692) significantly reduced RIF clearance 188 
(22).  No subjects in our study possessed the AADAC*3 allele, and inclusion of AADAC haplotype did 189 
not significantly improve the RIF model fit. Whilst the low incidence of these AADAC SNPs excluded 190 
their role in explaining inter-individual PK variability in this Malawian population, these genes are 191 
understudied. Similarly, the low incidence of one CES-1 SNP in our population does not exclude the 192 
possibility that polymorphisms in this gene are relevant in other populations, or that other 193 
mutations are important. Future work may describe higher SNP incidence in other settings, or 194 
identify alternative SNPs of relevance to drug exposure.    195 
 196 
The gene loci assessed here focussed on hepatic drug uptake and metabolism. Additional processes, 197 
including widely distributed mucosal P-glycoprotein transporters (29) and orphan nuclear receptor 198 
regulatory elements which influence gene induction (30) may also influence RIF metabolism. 199 
Investigation of these broader pharmacogenetic factors may be studied separately.  200 
 201 
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These data indicate that inter-individual variability in RIF PK amongst Malawian adults was not 202 
explained by polymorphisms in the candidate genes studied. They illustrate the importance of local 203 
ethnic background in the context of high SNP diversity within Africa and emphasise the need for 204 
caution in extrapolating findings across the continent. Growing recognition of the extent and clinical 205 
consequences of variable RIF PK (31-37) coupled with recent evidence that dose escalation is safe 206 
and tolerable (38) highlights the need for ongoing work to better define the relative importance of 207 
polymorphisms and non-genetic risk factors for low antibiotic exposure in a range of populations. 208 
 209 
There were several limitations to our study. Standard Fixed Dose Combination (FDC) tablets were 210 
used in treatment of the participants under field conditions, but we have not been able to account 211 
for the effect of quality of the potentially varying drug formulation on PK variability between the two 212 
cohorts. This reflects the reality of the TB drug supply chain in most countries. The use of sparse PK 213 
sampling at three fixed time points over six hours limited the precision of the estimates in each 214 
model, particularly for the absorption parameters. The use of data from a similar, intensively 215 
sampled cohort, to develop a population PK model mitigated this to some extent, achieving 216 
reasonable precision for the key PK parameter, AUC.  Finally, the size of the dataset was not 217 
predicated on this secondary pharmacogenetic analysis and the negative findings could be due to a 218 
relative lack of power. However, our study was larger than any reported African cohort to date and 219 
there are limitations on the number of PK profiles, even based on sparse sampling protocols, that 220 
can practically be obtained in the field situation.  On the other hand, it is widely recognised that 221 
candidate gene studies can be prone to chance findings which may not be subsequently replicated. 222 
 223 
In conclusion, high inter-individual variability in plasma exposure to RIF amongst Malawian adults 224 
with pulmonary TB cannot be explained by genetic heterogeneity in SLCO1B1, as suggested from 225 
other African populations. Similarly, the variability cannot be explained by the novel candidate gene 226 
SNPs in AADAC, CES-1 that were evaluated but the low frequency of variant genes in our population 227 
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does not exclude an association elsewhere. The true significance of pharmacogenetic influences on 228 
disposition of anti-tuberculosis drugs by comparison with non-genetic factors may only be 229 
established through consistent observation across geographically diverse and adequately powered 230 
cohort studies.  231 
 232 
Ethics  233 
Ethical approval was obtained from the College of Medicine Research Ethics Committee, University 234 
of Malawi, and the Research Ethics Committee of Liverpool School of Tropical Medicine.   235 
 236 
Materials and methods 237 
 238 
Study participants  239 
The sparse pharmacokinetic data sampling was conducted within a prospective cohort study 240 
conducted at QECH in Blantyre, Malawi from 2010-2012. Consenting adults aged 16-65 years with 241 
sputum smear-positive pulmonary TB were eligible. Exclusion criteria included haemoglobin<6g/dL, 242 
creatinine>177μmol/l, total bilirubin>51μmol/l, alanine transaminase >200IU/l, clinical status 243 
suggestive of imminent mortality (WHO Performance Score 4 (39)), pregnancy, TB treatment within 244 
five years, corticosteroid therapy or baseline resistance to rifampicin and isoniazid using the 245 
Genotype MTBDRplus 2.0 line probe assay (LPA, Hain Life Sciences). Patient characteristics have 246 
been reported previously (40). Participants received daily FDC tablets according to a WHO-approved 247 
weight-adjusted regimen (including rifampicin 8-12mg/kg) and standard National Tuberculosis 248 
Programme guidelines (41). Adherence was monitored by direct questioning and pill counts. All 249 
patients had point of care HIV serology. ART was provided per national protocols.  250 
The intensively sampled pharmacokinetic data used for the first stage of model construction was 251 
obtained from a prior study of adult patients with sputum smear-positive pulmonary TB at the same 252 
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hospital, conducted from 2007-2008. Recruitment criteria, patient characteristics and treatment 253 
protocols have also been reported previously (24), and were similar to the sparse sampling dataset.  254 
 255 
Genotyping  256 
Genomic DNA extraction and genotyping were performed from whole blood samples collected at 257 
baseline from each patient, as previously described (18). TaqMan real-time PCR using fluorescent 258 
probes for allelic discrimination was used to detect SNPs of two RIF transporting or metabolising 259 
genes: SLCO1B1 (rs11045819, rs4149032) and AADAC (rs1803155, rs61733693).  These SNPs are 260 
previously reported to have functional significance for RIF PK (18,22,23). An exploratory SNP 261 
(rs12149368) in CES-1 was also assessed. 262 
 263 
Drug plasma concentration determination  264 
For the sparse sampling cohort, blood collections to measure steady-state RIF concentrations were 265 
undertaken on day 14 or 21 after TB treatment initiation. Patients attended the study clinic after an 266 
overnight fast at 0730 hours. Samples were collected pre-dose, then 2 and 6 hours after 267 
medications. Plasma was separated by centrifugation and stored at -70oC until analysis.   268 
 269 
RIF concentrations were determined using a liquid chromatographic/tandem mass spectrometry 270 
method (24) using appropriate internal standards validated to internationally recognised acceptance 271 
criteria as previously described (42). The lower limit of quantification (LLQ) was 0.5 µg/ml for RIF. 5% 272 
of samples had RIF results below the LLQ. These data-points were handled by imputing a value which 273 
was 50% of the LLQ. 274 
 275 
Population pharmacokinetic analysis  276 
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A population PK model for RIF was developed using NONMEM® (version 7.2.0, ICON Development 277 
Solutions). Since the sparse sampling data contained little information on RIF absorption, a two-278 
stage model-building strategy was used. 279 
 280 
In the first stage, a dataset previously obtained from 47 adult tuberculosis patients in Blantyre 281 
employing intensive sampling and the same drug assay (24) was used to characterise the absorption 282 
phase.  No covariates were included. One- and two- compartment models with alternative models of 283 
absorption were fitted to the data using the First Order Conditional method of estimation with 284 
interaction. Among the models explored were simple first-order absorption or a sequence of zero- 285 
and first-order absorption incorporating either lag times or transit compartment absorption. 286 
Proportional, additive and combined proportional and additive error models were considered to 287 
describe residual variability. The minimal OFV (equal to -2 log likelihood) was used as a goodness-of-288 
fit metric with a decrease of 3.84 corresponding to a statistically significant difference between 289 
models (P=0.05, χ2 distribution, one degree of freedom). Residual plots were also examined.  290 
 291 
Once the appropriate structural model was established, the values of the absorption parameters 292 
were fixed and a second-stage analysis performed using data from the sparsely-sampled participants 293 
of the current study. The following covariates were explored: body weight, age, gender, HIV status 294 
and SNP genotypes.  295 
 296 
Exponential errors following a log-normal distribution were assumed for the description of inter-297 
individual variability in pharmacokinetic parameters, as shown in the following equation: 298 
 (1) θxi = θx *exp (ηxi) 299 
where θxi is pharmacokinetic parameter “x” of the ith individual; θx is the population parameter 300 
estimate; and ηxi is the log inter-individual variability for parameter “x” drawn from a normal 301 
distribution with a mean of zero and variance ω2. RIF was administered orally, CL and V represent 302 
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apparent values (CL/F and V/F, respectively, where F is the oral bioavailability, which was fixed to 1). 303 
An allometric weight model was applied to standardize the pharmacokinetic parameters using a 304 
standard weight (WTstd) of 70 kg. An allometric weight model for clearance parameters is given by 305 
CL/Fwt=ቀ ௐ்ௐ்௦௧ௗቁ
ଷ ସ⁄
 and for volume parameters is given V/Fwt=ቀ ௐ்ௐ்௦௧ௗቁ
ଵ
 where CL/Fwt and Vwt are the 306 
weight functions for clearance parameters and volume of distribution parameters, respectively, and 307 
WT is the individual weight value. 308 
 309 
Dichotomous covariates were introduced as a power model and continuous variables were modelled 310 
using a power model with normalized covariate:   311 
(2)  θi = θ1 × θcovX  312 
(3)  θi = θ1 ×(COVi/COVmedian) θcov 313 
where θi is the pharmacokinetic parameter of the ith individual; θ1 is the population parameter 314 
estimate; in equation 2 (dichotomous covariates) θcov is the ratio value of θi for the individuals 315 
X=0 or 1. In equation 3 (continuous covariates) COVi is the value of the covariate for the ith 316 
individual, COVmedian is the median value, θcov is the fraction of θi relative to the consider covariate 317 
effect.   318 
 319 
Genotype information was coded as an index variable, shown below for CL/F: 320 
TVCL =θ0+θ1*X1+ θ2*X2 321 
where θ0 is the typical value of CL/F for individuals with homozygosity, θ1 is the relative difference in 322 
CL/F for heterozygous for the mutant allele when X1=1, and θ2 is the relative difference in CL/F for 323 
patients homozygous for the mutant allele when X2=1.  324 
 325 
Graphical methods were used to explore the relationship of covariates versus individual predicted 326 
pharmacokinetic parameters. Each covariate was introduced separately into the model and only 327 
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retained if inclusion in the model produced a statistically significant decrease in OFV of 3.84 328 
(P≤0.05). A backwards elimination step was then carried out once all relevant covariates were 329 
incorporated and covariates were retained if their removal from the model produced a significant 330 
increase in OFV (>6.63 points; P≤0.01, χ2 distribution, one degree of freedom). 331 
 332 
To perform a VPC using Perl-speaks-NONMEM (PsN), 1000 datasets were simulated using the 333 
parameter estimates defined by the final model with the SIMULATION SUBPROBLEMS option of 334 
NONMEM®. From the simulated data, 90% prediction intervals (P5–P95) were constructed. Observed 335 
data from the original dataset were superimposed for both regimens. PsN was used to run a 336 
nonparametric bootstrap of 200 iterations to provide unbiased estimates of the standard errors and 337 
the 95% confidence intervals of the estimated parameters. 338 
 339 
Estimates of AUC0-∞ for RIF were calculated from simulated values of CL/F using the equation: 340 
ܣܷܥ଴ିஶ =
ܦ݋ݏ݁ ∈ ݈݈݉݅݅݃ݎܽ݉ݏ
ሺܥܮ ܨ⁄ ሻ  
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Figure legends 488 
Figure 1: Visual predictive check for the final rifampicin model. The lower, middle and upper lines 489 
are the 5th percentile, median and 95th percentile of the observed data, respectively. The shaded 490 
areas are the 95% CIs for the 5th percentile, median and 95th percentile of the simulated data.  491 
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 Taďle 1:  DeŵographiĐ aŶd ĐliŶiĐal desĐriptioŶ of Đohort 
CharaĐteristiĐ Total ;Ŷ=174Ϳ 
Age iŶ Ǉears, ŵediaŶ ;raŶgeͿ ϯϬ ;ϭϳ-ϲϭͿ 
Male seǆ, Ŷ ;%Ϳ ϭϮϭ ;ϲϵ.ϱͿ 
HIV iŶfeĐted, Ŷ ;%Ϳ ϵϴ ;ϱϲ.ϯͿ 
CDϰ iŶ HIV iŶfeĐted iŶ Đells/µl, ŵediaŶ ;raŶgeͿ ϭϳϰ ;ϲ-ϳϴϯͿ 
OŶ ART at ďaseliŶe if HIV iŶfeĐted, Ŷ ;%Ϳ Ϯϴ ;Ϯϴ.ϲͿ 
Weight iŶ kg, ŵediaŶ ;raŶgeͿ ϱϮ ;ϯϰ-ϳϰͿ 
AdhereŶĐe, Ŷ ;%Ϳ* 
  Missed Ŷo doses 
  Missed <Ϯ doses 
  Missed >Ϯ doses 
 
ϭϰϯ ;ϴϮ.ϮͿ 
ϭϬ ;ϱ.ϳͿ 
Ϯ ;ϭ.ϭͿ 
RifaŵpiĐiŶ / isoŶiazid dose ;ŵgͿ, Ŷ ;%Ϳ 
  ϯϬϬ / ϭϱϬ 
  ϰϱϬ / ϮϮϱ 
  ϲϬϬ / ϯϬϬ 
 
Ϯ ;ϭ.ϭͿ 
ϭϭϯ ;ϲϰ.ϵͿ 
ϱϵ ;ϯϯ.ϵͿ 
SLCOϭBϭ ŵutatioŶs 
rsϭϭϬϰϱϴϭϵ 
  ǁild ;CCͿ 
  heterozǇgote ;ACͿ 
  ǀariaŶt ;AAͿ 
 
ϭϱϬ ;ϴϲ.ϮͿ 
Ϯϰ ;ϭϯ.ϴͿ 
Ϭ ;ϬͿ 
rsϰϭϰϵϬϯϮ 
  ǁild ;TTͿ 
  heterozǇgote ;CTͿ 
  ǀariaŶt ;CCͿ 
ϴϵ ;ϱϭ.ϭͿ 
ϱϵ ;ϯϯ.ϵͿ 
Ϯϲ ;ϭϰ.ϵͿ 
AADAC ŵutatioŶs 
rsϭϴϬϯϭϱϱ 
  ǁild ;GGͿ 
  heterozǇgote ;CGͿ 
  ǀariaŶt ;CCͿ 
ϯ ;ϭ.ϳͿ 
ϴϬ ;ϰϲ.ϬͿ 
ϵϭ ;ϱϮ.ϯͿ 
rsϲϭϳϯϯϲϵϮ 
  ǁild ;TTͿ 
  heterozǇgote ;CTͿ 
  ǀariaŶt ;CCͿ 
 
ϭϳϰ ;ϭϬϬͿ 
Ϭ ;ϬͿ 
Ϭ ;ϬͿ 
AADAC haplotǇpe 
  AADAC*ϭ/*ϭ 
  AADAC*ϭ/*Ϯ 
  AADAC*Ϯ/*Ϯ 
ϯ ;ϭ.ϳͿ 
ϴϬ ;ϰϲ.ϬͿ 
ϵϭ ;ϱϮ.ϯͿ 
CESϭ ŵutatioŶs  
rsϭϮϭϰϵϯϲϴ 
  ǁild ;GGͿ 
  heterozǇgote ;CGͿ 
  ǀariaŶt ;CCͿ 
 
ϭϳϯ ;ϵϵ.ϰͿ 
ϭ ;Ϭ.ϲͿ 
Ϭ ;ϬͿ 
 
ART, aŶti-retroǀiral therapǇ; SNP, siŶgle ŶuĐleotide polǇŵorphisŵ; NATϮ, N-aĐetǇltraŶsferase Ϯ;  
SLCOϭBϭ, solute Đarrier orgaŶiĐ aŶioŶ traŶsporter faŵilǇ ŵeŵďer ϭBϭ; AADAC, arǇlaĐetaŵide 
deaĐetǇlase; CESϭ, ĐarďoǆǇlesterase ϭ. 
*AdhereŶĐe data oŶlǇ aǀailaďle for ϭϱϱ patieŶts. 
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Table Ϯ:  parameter value estimates for the base model stage ϭ 
Parameter  Typical value %RSE a 95% CI b CL/F ȋl/hȌ ͳͻ.ͷ ͵.ͻ ͳͺ.ʹ- ʹͲ.ͺ V/F ȋlȌ ʹ͹.ͳ ͳ͵.ͻ ʹͲ.ͻ- ͵͵.͵ 
Ka ȋh-ͳȌ Ͳ.ʹ͹͹ ͻ.ͺ Ͳ.ʹ͵- Ͳ.͵ʹ NN ͳ.ͷ Ͷͳ Ͳ.Ͳͻ-͵.ͻ MMT ȋhȌ Ͳ.͵ʹ͸ ͵ͷ Ͳ.Ͳͷ- ͳ.Ͳ   Random effects  ))VCL Ͳ.ͳ͸ͷ ͳͷ.͵ Ͳ.ͳʹ- Ͳ.ʹͲ ))VV Ͳ.Ͷʹͷ ʹ͹.ͳ Ͳ.ʹͷ- Ͳ.ͷͻ ))VMMT Ͳ.Ͳ͹Ͳ͸ ͹ͷ Ͳ.Ͳͳ- ͳ.͹ͻ Residual variability:      Proportional error ȋ%Ȍ Ͳ.ʹ͵ ͹.ͺ  Ͳ.ʹͲ- Ͳ.ʹ͸ 
CL/F, ĐlearaŶĐe (F is uŶkŶoǁŶ ďioaǀailaďility); V/F appareŶt ǀoluŵe of distriďutioŶ; Ka, aďsorptioŶ 
rate ĐoŶstaŶt NN, Ŷuŵďer of traŶsit ĐoŵpartŵeŶt; MMT, aďsorptioŶ ŵeaŶ traŶsit tiŵe; IIVCL, iŶter 
iŶdiǀidual ǀariaďility oŶ ĐlearaŶĐe; IIVV, iŶter iŶdiǀidual ǀariaďility oŶ ǀoluŵe; IIVMMT, iŶter 
iŶdiǀidual ǀariaďility oŶ aďsorptioŶ ŵeaŶ traŶsit tiŵe. a RSE, relatiǀe staŶdard error reported.  b CI, 
ĐoŶfideŶĐe iŶterǀal. 
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Table ϯ:  paraŵeter value estiŵates for the fiŶal ŵodel stage Ϯ 
Parameter  Typical value
(Shrinkage %) 
%RSE a 95% CI b CL/F ȋl/hȌ ͳͻ.͸ ͳʹ ͳ͸.͹-ʹʹ.ͷ V/F ȋlȌ ʹ͵.͸ ͻ ͳ͹.ͳ-͵Ͳ.ͳ 
Ka ȋh-ͳȌ Ͳ.ʹ͹͹ ȋF)XȌ  NN ͳ.ͷ ȋF)XȌ  MMT ȋhȌ Ͳ.͵ʹ͸ ȋF)XȌ  T(ETA_sex male ͳ.ʹ ͳ͵ ͳ.Ͳ-ͳ.͵ 
Random effects  ))VCL Ͳ.Ͳ͹͸ ȋʹʹȌ ʹͻ Ͳ.Ͳ͵͵-Ͳ.ͳͳ))VV Ͳ.͵ͻ͹ ȋʹͺȌ ʹͻ Ͳ.ͳ͹- Ͳ.͸͵))VMMT Ͳ.Ͳ͹Ͳ͸ȋF)XȌ  Residual variability:      Proportional error ȋ%Ȍ Ͳ.ʹʹ ͳʹ  Ͳ.ͳͻ-Ͳ.ʹ͸ 
CL/F, ĐlearaŶĐe (F is uŶkŶoǁŶ ďioaǀailaďilitǇ); V/F appareŶt ǀoluŵe of distriďutioŶ; NN, Ŷuŵďer of 
traŶsit ĐoŵpartŵeŶt; MMT, aďsorptioŶ ŵeaŶ traŶsit tiŵe; THETA_seǆ, fraĐtioŶal ĐhaŶge iŶ 
ĐlearaŶĐe for ŵales; IIVCL, iŶter iŶdiǀidual ǀariaďilitǇ oŶ ĐlearaŶĐe; IIVV, iŶter iŶdiǀidual ǀariaďilitǇ 
oŶ ǀoluŵe; IIVMMT, iŶter iŶdiǀidual ǀariaďilitǇ oŶ aďsorptioŶ ŵeaŶ traŶsit tiŵe. a RSE, relatiǀe 
staŶdard error reported.  b CI, ĐoŶfideŶĐe iŶterǀal. 
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